<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000627.v1.p1" parentStudy="phs000627.v1.p1" createDate="2013-06-14" modDate="2013-06-14">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Derek Y. Chiang, PhD</td><td>University of North Carolina, Chapel Hill, NC, USA</td></tr>
		<tr><td>Funding Source</td><td>University Cancer Research Fund (D.Y.C.)</td><td>University of North Carolina, Chapel Hill, NC, USA</td></tr>
		<tr><td>Funding Source</td><td>Fund from National Institutes of Health (Gad Getz)</td><td>Genome Sequencing Analysis Program and Platform, Broad Institute, Cambridge, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>UNC Hepatocellular Carcinoma Study by Exome Sequencing (HCCSES)</StudyNameEntrez>
	<StudyNameReportPage>University of North Carolina at Chapel Hill (UNC) Hepatocellular Carcinoma Study by Exome Sequencing (HCCSES)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
		<StudyType>Control Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma. As a prerequisite for individualized cancer treatment, we sought to characterize the landscape of recurrent somatic mutations in hepatocellular carcinoma. We performed whole exome sequencing on 87 hepatocellular carcinomas and matched normal adjacent tissues to an average coverage of 59x. The overall mutation rate was roughly 2 mutations per Mb, with a median of 45 non-synonymous mutations that altered the amino acid sequence (range 2 to 381). We found recurrent mutations in several genes with high transcript levels: TP53 (18%), CTNNB1 (10%), KEAP1 (8%), C16orf62 (8%), MLL4 (7%) and RAC2 (5%). Significantly affected gene families include the nucleotide-binding domain and leucine rich repeat containing family, calcium channel subunits, and histone methyltransferases. In particular, the MLL family methyltransferases for histone H3 lysine 4 were mutated in 20% of tumors. Conclusion: The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of hepatocellular carcinoma.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23728943"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="adult primary hepatocellular carcinoma"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Derek Y. Chiang, PhD</AttName>
			<Institution>University of North Carolina, Chapel Hill, NC, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>University Cancer Research Fund (D.Y.C.)</AttName>
			<Institution>University of North Carolina, Chapel Hill, NC, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Fund from National Institutes of Health (Gad Getz)</AttName>
			<Institution>Genome Sequencing Analysis Program and Platform, Broad Institute, Cambridge, MA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-MDS" longName="General Research Use (MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000627.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000627.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000627.v1.p1" FileName="eNCI_0158_DUC_7.8.2013.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (MDS)</ConsentName>
        <ConsentAbbrev>GRU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
